Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform
Speaker: Yanan Guo, Ph.D. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals GPCRs (G protein-coupled receptor) are the most abundant membrane protein in the human genome, and are targeted by approximately one-third of drugs on the market. However, the difficulty in antigen preparation and novel GPCR-targeting antibody screening has posed significant challenges […]
Read more
Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety
Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, in combination with the targeted delivery of cytotoxic payloads for potent tumor cell killing. […]
Read more
Joint, Lung, and Urinary Disease Models Offered at Biocytogen
Speaker: Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Inflammatory disease models are important preclinical research tools to study disease pathogenesis and uncover novel treatments. To directly evaluate the efficacy and safety of therapeutic drug candidates targeting these disorders, we can establish disease in wild-type and/or humanized mouse models. In this webinar, […]
Read more
Inflammatory Disease Modeling for Preclinical Studies
Speaker: Rebecca Soto, Ph.D. Scientist II/Associate Manager Content Marketing, Biocytogen Boston Provided a brief overview on molecular mechanisms driving disease progression. Discussed modeling inflammatory diseases in wild-type and humanized mice, including psoriasis, atopic dermatitis, delayed type hypersensitivity, inflammatory bowel disease and experimental autoimmune encephalomyelitis. Evaluated in vivo efficacy of therapeutic agents in preclinical inflammatory disease […]
Read more
Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen
Speaker: John Charpentier, Ph.D, Scientific Content Specialist, Biocytogen Boston Defined pharmacokinetics/pharmacodynamics (PK/PD) and useful parameters to measure them Discussed Biocytogen’s platforms suited for antibody PK/PD studies Introduced humanized mouse models useful for evaluation of PK/PD In vivo case studies and examples Q&A session
Read more
Preclinical Models to Investigate NK Cell-Targeted Immunotherapies
Speaker: Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston Reviewed the mechanisms driving NK cell activity in the context of immuno-oncology, and the types of NK-targeted immunotherapies currently under investigation Introduced experimental models used to evaluate these immunotherapies, including syngeneic models and xenograft models
Read more